Select Transactions

Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
Assembly Biosciences
Microbiome partnership with
Allergan
$2.6 billion
($50 million upfront)
January 2017
HealthCare Royalty Partners
Royalty-backed
acquisition financing
for undisclosed
spec pharma
Undisclosed
$100 million
February 2016
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE

The Future of the Global Pharmaceutical Industry

Torreya finds the global pharmaceutical industry is larger, innovating more rapidly, and likely to experience higher growth than previously thought.

Click here for Report Executive Summary   |    Click here for full Future of Global Pharmaceutical Industry Report

1 Based on Torreya econometric model relating OECD estimates of future GDP growth to growth estimates for the pharmaceutical sector.